Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/value-creation-potential-of-intellectual-capital-in-biotechnology-MQK0LbJWpS
References (26)
-
P. Bukh, J. Mouritsen, H. Larsen, Gitte Hansen, Gustav Jeppesen, Benedikte Stakemann, Darlush Rezai, Bjarne Andersen, Sten Rasmussen, L. Nielsen (2000)
A Guide for Intellectual Capital Statements - A Key to Knowledge Management -
(2002)
Ownership and financial structures in Finnish biotech SMEs. ETLA discussion paper no. 835, The Research Institute of the Finnish Economy (ETLA) -
Karl-Erik Sveiby (1997)
The New Organizational Wealth: Managing and Measuring Knowledge-Based Assets -
G. Ahonen (2000)
Generative and Commercially Exploitable Intangible Assets -
(1995)
seminal model in which they interpret how the tacit knowledge is converted to explicit knowledge and back to the tacit knowledge of other individuals and groups -
I. Linnosmaa, R. Hermans, T. Hallinen (2004)
Price-cost margin in the pharmaceutical industry. Empirical evidence from Finland.The European journal of health economics : HEPAC : health economics in prevention and care, 5 2
-
R. Hall (1999)
The Stock Market and Capital AccumulationLSN: Law & Finance: Empirical (Topic)
-
(1990)
Kunskapsledning. 101 ra˚d till ledare i kunskapsintensiva organisationer -
(2001)
Intangible assets, measurement, drivers, usefulness. Unpublished discussion paper, Boston University and New York University, 32pp -
(2002)
National Intellectual Capital Index: Intellectual Capital Development in the Arab Region -
Tomi Hussi (2003)
RECONFIGURING KNOWLEDGE MANAGEMENT -
Judith Cumby, Joan Conrod (2001)
Non‐financial performance measures in the Canadian biotechnology industryJournal of Intellectual Capital, 2
-
Hanna Kuusi (2001)
Finland a European Leader in Biotechnology -
C. Phillips (1971)
Industrial Market Structure and Economic Performance -
Tomi Hussi, G. Ahonen (2002)
Managing intangible assets – a question of integration and delicate balanceJournal of Intellectual Capital, 3
-
(2003)
Principles of Corporate Financing (6th ed) -
David Deeds (2001)
The Role of R&D Intensity, Technical Development and Absorptive Capacity in Creating Entrepreneurial Wealth in High Technology Start-UpsJournal of Engineering and Technology Management, 18
-
N. Bontis (2000)
Managing organizational knowledge by diagnosing intellectual capital : framing and advancing the state of the field -
R. Kroszner, Philip Strahan (1998)
What Drives Deregulation? The Economics and Politics of the Relaxation of Bank Branching RestrictionsBanking & Financial Institutions eJournal
-
(1997)
Intellectual Capital – The Proven Way to Establish your Company’s Real Value by Measuring its Hidden Brainpower. London: Judy Piatkus -
(2002)
Measuring intellectual capital’s dynamic value: The IC-dVals approach -
Linnosmaa Linnosmaa, Hermans Hermans, Hallinen Hallinen (2004)
Price–cost margin in the pharmaceutical industryThe European Journal of Health Economics
-
M. Darby, L. Zucker (2002)
Going Public When You Can in BiotechnologyERPN: Industry Studies (Sub-Topic)
-
B. Lev, Theodore Sougiannis (1996)
The capitalization, amortization, and value-relevance of R&DJournal of Accounting and Economics, 21
-
J. Hodgson (2003)
The Human Value of the Enterprise: Valuing People as Assets – Monitoring, Measuring, ManagingLeadership & Organization Development Journal, 24
-
S. Mann (1999)
Intellectual Capital: The New Wealth of OrganizationsLeadership & Organization Development Journal, 20
- Publisher
- Wiley
- Copyright
- Copyright © 2005 Wiley Subscription Services, Inc., A Wiley Company
- ISSN
- 0033-6807
- eISSN
- 1467-9310
- DOI
- 10.1111/j.1467-9310.2005.00381.x
- Publisher site
- See Article on Publisher Site
Abstract
The objective of the study was to empirically verify impacts of intellectual capital (IC) to the anticipated future sales of small‐ and medium‐sized companies within the biotechnology industry. The study creates and develops tools for the valuation of companies by relating the existing intangibles and the expected value creation of the companies in that industry displaying high growth prospects but long and insecure product development phases. Theoretically, IC is divided into the following three categories: human capital (HC), structural capital (SC), and relational capital (RC). In the empirical setting, survey data of small‐ and medium‐sized Finnish biotechnology companies are used. In the econometric analyses, the interactions, or empirical co‐variation, between the three categories of IC explain two‐thirds of the variance in the anticipated future sales of the sample companies. Thus, it seems that a well‐balanced combination of HC, SC, and RC implies value creation potential and high anticipated future sales.
Journal
R & D Management – Wiley
Published: Mar 1, 2005